Barclays analyst Brandon Oglenski lowered the firm’s price target on RXO Inc. (RXO) to $15 from $17 and keeps an Overweight rating on the shares post the Q3 report. The company’s Q4 outlook is materially below expectations and sets up for a fourth year in 2026 of trough level earnings forecasts, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXO: